Fast-Made cell therapy tested as potential Game-Changer for tough lupus cases
NCT ID NCT07233642
Summary
This early-stage study is testing a new, quickly manufactured cell therapy for people with severe lupus that hasn't responded to standard drugs. The therapy, called CAR-T, involves taking a patient's own immune cells, modifying them to target harmful B cells, and reinfusing them. The main goals are to see if this approach is safe and if it can reduce lupus disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.